Table 1: Combined Oral Contraception (COC) available in Ireland Synthetic progestogen (progestin)* Brand Dosage oestrogen / progestogen* Reimbursed price (one month supply unless otherwise stated) ********************************** SECOND GENERATION ***************************************************************** Levonorgestrel MICROLITE 20mcg / 100mcg 21, €4.05 LEONORE 20mcg / 100mcg 63, €9.47 (3 months) OVRANETTE 30mcg / 150mcg 21, €0.77 LOGYNON 30/50mg; 40/75mcg; 30/125mcg 21, […]
Combined oral contraceptives – side-effects and solutions
September 1, 2013 by Leave a Comment
Download pdf Table 2: Side-effects of combined oral contraceptives SIDE EFFECT POSSIBLE CAUSE(S) POSSIBLE SOLUTIONS SUGGESTED BRANDS NAUSEA Too much oestrogen Reduce oestrogen strength Leonore, Microlite, Mercilon,Yaz, Yasminelle Take after food/ in evenings Zoely Consider non oral / non oestrogen options Nuvaring, POP, LARC, etc. BREAK THROUGH BLEEDING Too little oestrogen Increase oestrogen strength Estelle, […]
Codeine*: Restricted use as analgesic in children / adolescents
September 1, 2013 by Leave a Comment
The use of codeine for analgesia in children and adolescents under 18 has been restricted after an EU review1. This review was triggered by reports in children who received codeine for pain control after tonsillectomy or adenoidectomy (or both), for obstructive sleep apnoea and who developed rare, but life-threatening adverse events, including death. Codeine is […]
FDA perspective reinforces safety profile of Pradaxa
September 1, 2013 by Leave a Comment
The U.S. Food and Drug Administration (FDA) stated that bleeding rates associated with new use of Pradaxa (dabigatran etexilate) do not appear to be higher than those with new use of warfarin.1,2 Dabigatran etexilate is a direct thrombin inhibitor (DTI). DTIs act by specifically blocking the activity of thrombin (both free and clot-bound), an enzyme […]
Eliquis
September 1, 2013 by Leave a Comment
Company: Bristol-Myers Squibb/Pfizer EEIG Legal category: Prescription. GMS. Sport permitted. Active ingredient: Apixaban 5mg. Description: Pink, oval film-coated tablets marked 894 on one side and 5 on reverse. Presentation: 5mg-56, €65.80. Indications: Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), and ≥1 risk factors, e.g. prior stroke or TIA, […]
Meroponia
September 1, 2013 by Leave a Comment
Company: Clonmel Healthcare Ltd. Legal category: Prescription. Sport permitted. Active ingredient: Meropenem 500mg, 1g. Description: Powder for solution for injection or infusion. Presentation: 500mg-10, €79.30; 1g-10, €158.65. Indications: Treatment of pneumonia, broncho-pulmonary infections in cystic fibrosis; complicated urinary tract, intra-abdominal, skin and soft tissue infections; intra- and post-partum infections, acute bacterial meningitis. Management of febrile […]
Raporsin
September 1, 2013 by Leave a Comment
Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Doxazosin (as mesilate) 4mg, 8mg. Description: White, round, biconvex, prolonged release tablets marked DL or DH respectively. Presentation: 4mg-28, €GMS to be confirmed; 8mg-28, €6.55. Indications: Essential hypertension. Symptomatic treatment of benign prostatic hyperplasia (BPH). Pharmacology: Administration of doxazosin in hypertensive patients causes […]
Gemzar to be Discontinued
September 1, 2013 by Leave a Comment
Eli Lilly & Co. (Ireland) Ltd. would like to inform you that on the 12th of June 2013, they officially notified the Department of Health and the Irish Medicines Board of the intention to cease supply of Gemzar 200mg and 1g powder for solution for infusion in Ireland due to low volume usage, effective 15th […]
Loading ...
